Sin-Aye Park1, James Platt1, Jong Woo Lee1, Francesc López-Giráldez1, Roy S Herbst1, Ja Seok Koo2. 1. Section of Medical Oncology, Department of Internal Medicine (SAP, JWL, RSH, JSK) and Translational Research Program (RSH, JSK), Yale Comprehensive Cancer Center, Departments of Pathology and Medical Oncology (JP), Yale School of Medicine, New Haven, CT; Yale Center for Genome Analysis, Yale University, Orange, CT (FLG). 2. Section of Medical Oncology, Department of Internal Medicine (SAP, JWL, RSH, JSK) and Translational Research Program (RSH, JSK), Yale Comprehensive Cancer Center, Departments of Pathology and Medical Oncology (JP), Yale School of Medicine, New Haven, CT; Yale Center for Genome Analysis, Yale University, Orange, CT (FLG). jpeter.koo@yale.edu.
Abstract
BACKGROUND: The E2F members have been divided into transcription activators (E2F1-E2F3) and repressors (E2F4-E2F8). E2F8 with E2F7 has been known to play an important physiologic role in embryonic development and cell cycle regulation by repressing E2F1. However, the function of E2F8 in cancer cells is unknown. METHODS: E2F8 expression was assessed by immunoblotting or immunofluorescence staining in human lung cancer (LC) cells and tissues from LC patients (n = 45). Cell proliferation, colony formation, and invasion analysis were performed to evaluate the role of E2F8 in LC. Microarray analysis was used to determine the target genes of E2F8. The regulation of E2F8 on the expression of ubiquitin-like PHD and RING domain-containing 1 (UHRF1), one of E2F8 target genes, was determined using chromatin immunoprecipitation and promoter activity assays. Human LC xenograft models were used to determine the effects of inhibiting E2F8 by siRNAs (n = 7 per group) or antisense morpholino (n = 8 per group) on tumor growth. Survival was analyzed using the Kaplan-Meier method and group differences by the Student's t test. All statistical tests were two-sided. RESULTS: LC tumors overexpressed E2F8 compared with normal lung tissues. Depletion of E2F8 inhibited cell proliferation and tumor growth. E2F8 knockdown statistically significantly reduced the expression of UHRF1 (~60%-70%, P < .001), and the direct binding of E2F8 on the promoter of UHRF1 was identified. Kaplan-Meier analysis with a public database showed prognostic significance of aberrant E2F8 expression in LC (HR = 1.91 95% CI = 1.21 to 3.01 in chemo-naïve patients, P = .0047). CONCLUSIONS: We demonstrated that E2F8 is overexpressed in LC and is required for the growth of LC cells. These findings implicate E2F8 as a novel therapeutic target for LC treatment.
BACKGROUND: The E2F members have been divided into transcription activators (E2F1-E2F3) and repressors (E2F4-E2F8). E2F8 with E2F7 has been known to play an important physiologic role in embryonic development and cell cycle regulation by repressing E2F1. However, the function of E2F8 in cancer cells is unknown. METHODS:E2F8 expression was assessed by immunoblotting or immunofluorescence staining in humanlung cancer (LC) cells and tissues from LC patients (n = 45). Cell proliferation, colony formation, and invasion analysis were performed to evaluate the role of E2F8 in LC. Microarray analysis was used to determine the target genes of E2F8. The regulation of E2F8 on the expression of ubiquitin-like PHD and RING domain-containing 1 (UHRF1), one of E2F8 target genes, was determined using chromatin immunoprecipitation and promoter activity assays. Human LC xenograft models were used to determine the effects of inhibiting E2F8 by siRNAs (n = 7 per group) or antisense morpholino (n = 8 per group) on tumor growth. Survival was analyzed using the Kaplan-Meier method and group differences by the Student's t test. All statistical tests were two-sided. RESULTS: LC tumors overexpressed E2F8 compared with normal lung tissues. Depletion of E2F8 inhibited cell proliferation and tumor growth. E2F8 knockdown statistically significantly reduced the expression of UHRF1 (~60%-70%, P < .001), and the direct binding of E2F8 on the promoter of UHRF1 was identified. Kaplan-Meier analysis with a public database showed prognostic significance of aberrant E2F8 expression in LC (HR = 1.91 95% CI = 1.21 to 3.01 in chemo-naïve patients, P = .0047). CONCLUSIONS: We demonstrated that E2F8 is overexpressed in LC and is required for the growth of LC cells. These findings implicate E2F8 as a novel therapeutic target for LC treatment.
Authors: Justin B Maxhimer; David R Soto-Pantoja; Lisa A Ridnour; Hubert B Shih; William G Degraff; Maria Tsokos; David A Wink; Jeff S Isenberg; David D Roberts Journal: Sci Transl Med Date: 2009-10-21 Impact factor: 17.956
Authors: David C Silvestre; Germán A Gil; Nicolás Tomasini; Daniela F Bussolino; Beatriz L Caputto Journal: PLoS One Date: 2010-03-04 Impact factor: 3.240
Authors: Liliana Endo-Munoz; Alison Dahler; Ngari Teakle; Danny Rickwood; Mehlika Hazar-Rethinam; Ibtissam Abdul-Jabbar; Scott Sommerville; Ian Dickinson; Pritinder Kaur; Sophie Paquet-Fifield; Nicholas Saunders Journal: Cancer Res Date: 2009-02-17 Impact factor: 12.701
Authors: David M Jackman; Vincent A Miller; Leigh-Anne Cioffredi; Beow Y Yeap; Pasi A Jänne; Gregory J Riely; Marielle Gallegos Ruiz; Giuseppe Giaccone; Lecia V Sequist; Bruce E Johnson Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: David G J Cucchi; Costa Bachas; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Zinia J Kwidama; Gerrit J Schuurhuis; Yehuda G Assaraf; Valérie de Haas; Gertjan J L Kaspers; Jacqueline Cloos Journal: Cancers (Basel) Date: 2020-05-15 Impact factor: 6.639
Authors: Marco Kramer; Diogo Ribeiro; Marie Arsenian-Henriksson; Thomas Deller; Hermann Rohrer Journal: J Neurosci Date: 2016-10-05 Impact factor: 6.167
Authors: Lindsey N Kent; Jessica B Rakijas; Shusil K Pandit; Bart Westendorp; Hui-Zi Chen; Justin T Huntington; Xing Tang; Sooin Bae; Arunima Srivastava; Shantibhusan Senapati; Christopher Koivisto; Chelsea K Martin; Maria C Cuitino; Miguel Perez; Julian M Clouse; Veda Chokshi; Neelam Shinde; Raleigh Kladney; Daokun Sun; Antonio Perez-Castro; Ramadhan B Matondo; Sathidpak Nantasanti; Michal Mokry; Kun Huang; Raghu Machiraju; Soledad Fernandez; Thomas J Rosol; Vincenzo Coppola; Kamal S Pohar; James M Pipas; Carl R Schmidt; Alain de Bruin; Gustavo Leone Journal: J Clin Invest Date: 2016-07-25 Impact factor: 14.808
Authors: Min Huang; Jasmine Zeki; Nathan Sumarsono; Garry L Coles; Jordan S Taylor; Enrico Danzer; Matias Bruzoni; Florette K Hazard; Norman J Lacayo; Kathleen M Sakamoto; James C Y Dunn; Sheri L Spunt; Bill Chiu Journal: Cancer Res Date: 2020-01-03 Impact factor: 12.701
Authors: Eva Moreno; Shusil K Pandit; Mathilda J M Toussaint; Laura Bongiovanni; Liesbeth Harkema; Saskia C van Essen; Elsbeth A van Liere; Bart Westendorp; Alain de Bruin Journal: Cancers (Basel) Date: 2021-04-23 Impact factor: 6.639